Seminars in Oncology
Volume 36, Issue 2 , Pages 112-125 , April 2009

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer Stat. 2008;58:71–96
  2. Markman M, Reichman B, Hakes T, Jones W, Lewis JL, Rubin S, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9:1801–1805
  3. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207–211
  4. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989;59:650–653
  5. Dizon DS, Dupont J, Anderson S, Sabbatini P, Hummer A, Aghajanian C, et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel: the Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol. 2003;91:584–590
  6. Parmar MK LJ, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106
  7. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–4707
  8. Orlando M, Costanzo MV, Chacon RD, Tajer CD. Randomized trials of combination chemotherapy (combo) versus monotherapy (mono) in relapsed ovarian carcinoma (ROC): a meta-analysis of published data. [abstract] J Clin Oncol. 2007;25(Suppl):5524;(meeting abstracts)
  9. Ferrero JM, Weber B, Geay JF, Lepille D, Orfeuvre H, Combe M, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol. 2007;18:263–268
  10. du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol. 2007;107:518–525
  11. Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol. 2008;108:90–94
  12. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18:3093–3100
  13. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000;78:369–372
  14. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987–993
  15. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312–3322
  16. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890–896
  17. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8
  18. O'Byrne KJ, Bliss PB, Graham JD, Gerber J, Vasey PA, Khanna S, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. [abstract] Proc Am Soc Clin Oncol. 2002;21:808
  19. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811–2818
  20. Bilgin TOS, Yalçin OT, Zorlu G, Vardar MA, Ozerkan K. Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. Eur J Gynaecol Oncol. 2003;24:169–170
  21. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 2003;88:266–269
  22. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 1998;9:1343–1345
  23. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86:1530–1533
  24. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003;90:593–596
  25. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996;63:89–93
  26. Silver DF, Piver MS. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol. 1999;22:450
  27. Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JPD. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10:853–855
  28. Nelson R, Tarassoff P. Dyspnoea with gemcitabine is commonly seen, often disease related, transient, and rarely severe. Eur J Cancer. 1995;31(Suppl 6):S197–S198
  29. Pavlakis NBD, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286–291
  30. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111:273–279
  31. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12:1748–1753
  32. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol. 1996;23(Suppl 12):40–47
  33. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200
  34. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708
  35. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997;15:187–192
  36. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002;20:2365–2369
  37. Dunder IBB, Atabekoglu C, Bilgin T. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. Eur J Gynaecol Oncol. 2005;26:79–82
  38. Ghamande S, Lele S, Marchetti D, Baker T, Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer. 2003;13:142–147
  39. Kita T, Kikuchi Y, Takano M, Suzuki M, Oowada M, Konno R, et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol. 2004;92:813–818
  40. Le T, Hopkins L, Baines KA, Rambout L, Al Hayki M, Kee Fung MF. Prospective evaluationsof continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2006;102:49–53
  41. Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436–440
  42. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994;12:2301–2308
  43. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res. 1996;2:837–842
  44. Piccart MJ, Gore M, Huinink WTB, Van Oosterom A, Verweij J, Wanders J, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst. 1995;87(9):676–681
  45. Katsumata N, Tsunematsu R, Tanaka K, Terashima Y, Ogita S, Hoshiai H, et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study. Ann Oncol. 2000;11:1531–1536
  46. Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004;95:624–631
  47. Komiyama STH, Asai S, Dokoh J, Ishikawa M, Mikami M. A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer. Eur J Gynaecol Oncol. 2005;26:299–302
  48. Tinker AV, Gebski V, Fitzharris B, Buck M, Stuart-Harris R, Beale P, et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel—ANZGOG 02-01. Gynecol Oncol. 2007;104:647–653
  49. Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998;16:2233–2237
  50. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183–2193
  51. Eckhardt S, Hernádi Z, Thurzó L, Telekes A, Sopkova B, Mechl Z, et al. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer (Results of the South-East European Oncology Group (SEEOG) study). Oncology. 1990;47:289–295
  52. Edmonson JH, Decker DG, Malkasian GD, Webb MJ, Jorgensen EO. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents. Gynecol Oncol. 1978;6:7–9
  53. Maskens AP, Armand JP, Lacave AJ, De Jager RL, Hansen HH, Wolff JP. Phase II clinical trial of VP-16-213 in ovarian cancer. Cancer Treat Rep. 1981;65:329–330
  54. Alici S, Saip P, Eralp Y, Aydiner A, Topuz E. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am J Clin Oncol. 2003;26:358–362
  55. de Wit R, van der Burg MEL, Gaast Avd, Logmans A, Stoter G, Verweij J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol. 1994;5:656–657
  56. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol. 1994;12:60–63
  57. Markman M, Hakes T, Reichman B, Curtin J, Barakat R, Rubin S, et al. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol. 1992;119:55–57
  58. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405–410
  59. Seymour MT, Mansi JL, Gallagher CJ, Gore ME, Harper PG, Evans TR, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer. 1994;69:191–195
  60. Bajetta E, Di Leo A, Biganzoli L, Mariani L, Cappuzzo F, Di Bartolomeo M, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1996;14:2546–2551
  61. Burger RA, DiSaia PJ, Roberts JA, O'Rourke M, Gershenson DM, Homesley HD, et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol. 1999;72:148–153
  62. Sorensen P, Hoyer M, Jakobsen A, Malmstrom H, Havsteen H, Bertelsen K. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81:58–62
  63. Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, et al. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol. 1998;70:272–274
  64. Sutton G. Ifosfamide and mesna in epithelial ovarian carcinoma. Gynecol Oncol. 1993;51:104–108
  65. Hasan J, Jayson GC. Oral melphalan as a treatment for platinum-resistant ovarian cancer. Br J Cancer. 2003;88:1828–1830
  66. Johnson BL, Fisher RI, Bender RA, DeVita VT, Chabner BA, Young RC. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer. 1978;42:2157–2161
  67. Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol Oncol. 2003;88:118–122
  68. Manetta A, Tewari K, Podczaski ES. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol. 1997;66:20–26
  69. Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998;69:226–229
  70. Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol. 1992;47:282–286
  71. Chan JK, Loizzi V, Manetta A, Berman ML. Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol Oncol. 2004;92:368–371
  72. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol. 2002;84:201–209
  73. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol. 2006;32:875–886
  74. Bhoola SM, Alvarez RD. Novel therapies for recurrent ovarian cancer management. Expert Rev Anticancer Ther. 2004;4:437–448
  75. Darcy KM, Schilder RJ. Relevant molecular markers and targets. Gynecol Oncol. 2006;103(Suppl 1):6–13
  76. See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest. 2004;22(Suppl 2):29–44
  77. Martin L, Schilder RJ. Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects. J Natl Compr Cancer Network. 2006;4:955–966
  78. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:5165–5171
  79. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180–5186
  80. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. [abstract 2] J Clin Oncol. 2005;23(Suppl 2):(meeting abstracts)
  81. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  82. Sandler AB, Gray R, Brahmer J, Dowlati A, Schiller JH, Perry MC, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial—E4599. [abstract] J Clin Oncol. 2005;23(Suppl):LBA4;(meeting abstracts)
  83. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol. 2008;26:76–82
  84. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol. 2006;102:134–139
  85. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102:425–428
  86. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6:373–378
  87. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–985
  88. Hochster HS. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Semin Oncol. 2006;33(Suppl 10):S8–S14
  89. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917
  90. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921
  91. Fong PC, Boss DS, Carden CP, Roelvink M, De Greve J, Gourley J, et al. A phase I trial of AZD2281 (KU-0059436), a PARP inhibitor with single agent anticancer activity in patients with BRCA deficient tumours, particularly ovarian cancer. [abstract 5510] J Clin Oncol. 2008;26:May 20 Suppl
  92. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res. 2007;13:1383–1388
  93. Chou H-H, Wang K-L, Chen C-A, Wei L-H, Lai C-H, Hsieh C-Y, et al. Pegylated liposomal doxorubicin (Lipo-Dox(R)) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese Gynecologic Oncology Group study with long-term follow-up. Gynecol Oncol. 2006;101:423–428
  94. Lorusso DNA, Testa A, D'Agostino G, Scambia G, Ferrandina G. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients (May a new treatment schedule improve toxicity profile?). Oncology. 2004;67:243–249
  95. Sehouli J, Oskay-Ozcelik G, Kuhne J, Stengel D, Hindenburg HJ, Klare P, et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol. 2006;17:957–961
  96. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14:1552–1557
  97. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 1996;14:3056–3061
  98. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997;66:480–486
  99. Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345–3352
  100. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:1062–1067
  101. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol. 2000;79:116–119
  102. Brown JV, Peters WA, Rettenmaier MA, Graham CL, Smith MR, Drescher CW, et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol. 2003;88:136–140
  103. Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol. 2001;83:394–399
  104. Spannuth WA, Leath CA, Huh WK, Barnes MN, Davidson SA, Kilgore LC, et al. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol. 2007;104:591–595
  105. Safra T, Menczer J, Bernstein R, Shpigel S, Inbar MJ, Grisaru D, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol. 2007;105:205–210
  106. Brown JV, Rettenmaier MA, Lopez KL, Graham C, Micha JP, Goldstein B. A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. Int J Gynecol Cancer. 2008;18:249–254
  107. Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol. 2000;78:228–234
  108. Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R, et al. New York Gynecologic Oncology Group Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 1999;17:2553–2561
  109. Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2000;77:112–115
  110. Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kristensen G, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol. 2001;19:3967–3975
  111. du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum. Eur J Cancer. 1997;33:379–384
  112. Nardi M, Aloe A, De Marco S, Cognetti F, Iacovelli A, Atlante G, et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol. 1997;20:230–232
  113. Pectasides DPM, Varthalitis J, Mylonakis A, Kostopoulou M, Dimitriadis M, Athanassiou A. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer (Phase II study). Oncology. 1998;55:228–234
  114. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol. 2000;79:211–215
  115. Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002;20:1232–1237
  116. Lorenz E, Hagen B, Himmelmann A, Kjorstad K, Onsrud M, Tingulstad S, et al. A phase II study of biweekly administration of paclitaxel in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer. 1999;9:373–376
  117. Kaye S, Piccart M, Aapro M, Kavanagh J. Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. Eur J Cancer. 1995;31A(Suppl 4):S14–S17
  118. Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes EdP, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant mullerian carcinoma. J Clin Oncol. 2000;18:2733–2739
  119. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130–135
  120. Markman M, Zanotti K, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol. 2003;91:573–576

 Supported in part by the ovarian SPORE at Fox Chase Cancer Center (P50CA083638).

PII: S0093-7754(08)00260-1

doi: 10.1053/j.seminoncol.2008.12.003

Seminars in Oncology
Volume 36, Issue 2 , Pages 112-125 , April 2009

Article Tools